New opportunities in the diagnosis and treatment of inflammatory bowel diseases-Reference-Cited by-同舟云学术

New opportunities in the diagnosis and treatment of inflammatory bowel diseases

Published:2024-01-17 Issue:9 Volume: Page:13-19
ISSN:1682-8658
Container-title:Experimental and Clinical Gastroenterology
language:
Short-container-title:jour

Author:

Pershko A. M.¹,Grinevich V. B.¹^ORCID,Ivanyuk E. S.¹^ORCID

Affiliation:

1. S. M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation

Abstract

The study of inflammatory bowel disease is characterized by dynamism and new discoveries. Subtle and new mechanisms of participation of genetic and environmental factors in the pathogenesis of inflammatory bowel diseases have been deciphered, as well as new classes of drugs have appeared that allow influencing many parts of the inflammatory process. However, the paradox of the situation lies in the fact that the more recent advances and discoveries in the field of biology and medicine, the more “gray spots” become in our understanding of the pathogenesis and approaches to the treatment of this category of patients. At the same time, the fundamental problems of IBD, related to reducing the risk of surgical interventions and restoring the quality of life of patients to the population level, are far from being resolved. The article discusses new methodological approaches to the treatment of patients with inflammatory bowel diseases using new classes of cytostatics and granulocyte-macrophage colony-stimulating factors.

Publisher

LLC Global Media Technology

Reference43 articles.

1. Pershko A.M. [Clinical and morphological variants of nonspecific ulcerative colitis: prognosis of the course and approaches to therapy (clinical and experimental study)]. Diss… med. Science. St. Petersburg, 2000. 38 p. (in Russ.)@@ Pershko A. M. Kliniko-morfologicheskie varianty nespetsificheskogo yazvennogo kolita: prognozirovanie techeniya i podkhody k terapii (kliniko-eksperimental'noe issledovanie). \\Avtoferat dokt. dissertatsii. -SPb, 2000. - 38 s.

2. Pershko A.M., Pronin I. A., Gubonina I. V. [Clinical efficacy of pulse therapy with metipred and cyclophosphamide in patients with acute forms of ulcerative colitis]. [Materials of the scientific-practical conference. Advanced medical technologies for practical healthcare]. St. Petersburg, 2008. 283 P. (in Russ.) @@ Pershko A. M., Pronin I. A., Gubonina I. V. Klinicheskaya effektivnost' pul's-terapii metipredom i tsiklofosfamidom u bol'nykh s ostrymi formami nespetsificheskogo yazvennogo kolita. Peredovye meditsinskie tekhnologii prakticheskomu zdravokhraneniyu. Materialy nauchno-prakticheskoi konferentsii. - SPb, 2008. -S.283.

3. Ashton J.J., Andreoletti G., Coelho T., Haggarty R., Batra A., Afzal N. A., Beattie R. M., Ennis S. Identification of Variants in Genes Associated with Single-gene Inflammatory Bowel Disease by Whole-exome Sequencing. Inflamm Bowel Dis. 2016 Oct;22(10):2317-27. doi: 10.1097/MIB.0000000000000890.

4. Autschbach F., Braunstein J., Helmke B., Zuna I., Schürmann G., Niemir Z. I., Wallich R., Otto H. F., Meuer S. C. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol. 1998 Jul;153(1):121-30. doi: 10.1016/S0002-9440(10)65552-6.

5. Oh S.H., Baek J., Kim K. M., Lee E. J., et al. Is Whole Exome Sequencing Clinically Practical in the Management of Pediatric Crohn’s Disease? Gut Liver. 2015 Nov 23;9(6):767-75. doi: 10.5009/gnl15176.